105 related articles for article (PubMed ID: 12091625)
1. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.2. Long-term immunosuppression. Therapy conversion.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():20-1. PubMed ID: 12091625
[TBL] [Abstract][Full Text] [Related]
2. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.4. Long-term immunosuppression. Non-compliance.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():23-4. PubMed ID: 12091627
[TBL] [Abstract][Full Text] [Related]
3. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.3.3. Long-term immunosuppression. Toxicity of immunosuppression.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():21-3. PubMed ID: 12091626
[TBL] [Abstract][Full Text] [Related]
4. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.2 Chronic graft dysfunction. Immunological factors (alloimmunity).
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():8-11. PubMed ID: 12091618
[TBL] [Abstract][Full Text] [Related]
5. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.6. Cardiovascular risks. Smoking.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():29. PubMed ID: 12091634
[TBL] [Abstract][Full Text] [Related]
6. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():28-9. PubMed ID: 12091633
[TBL] [Abstract][Full Text] [Related]
7. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.7. Cardiovascular risks. Obesity and weight gain.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():29-30. PubMed ID: 12091635
[TBL] [Abstract][Full Text] [Related]
8. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.3. Haematological complications. Erythrocytosis.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():49-50. PubMed ID: 12091649
[TBL] [Abstract][Full Text] [Related]
9. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():1-67. PubMed ID: 12484407
[No Abstract] [Full Text] [Related]
10. Current and evolving immunosuppressive regimens in kidney transplantation.
Gaston RS
Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S3-21. PubMed ID: 16567239
[TBL] [Abstract][Full Text] [Related]
11. Renal transplantation, immunosuppression and the skin: an update.
Moloney FJ; de Freitas D; Conlon PJ; Murphy GM
Photodermatol Photoimmunol Photomed; 2005 Feb; 21(1):1-8. PubMed ID: 15634217
[TBL] [Abstract][Full Text] [Related]
12. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
[TBL] [Abstract][Full Text] [Related]
13. [Immune monitoring of kidney transplant recipients: can markers predictive of over-immunosuppression be identified?].
Saas P; Courivaud C; Bamoulid J; Garnache-Ottou F; Seilles E; Ducloux D
Ann Pharm Fr; 2008 Mar; 66(2):115-21. PubMed ID: 18570910
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing long-term outcomes following renal transplantation: a review.
Shrestha BM; Haylor JL
JNMA J Nepal Med Assoc; 2007; 46(167):136-42. PubMed ID: 18274571
[TBL] [Abstract][Full Text] [Related]
16. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive agents in pediatric renal transplantation].
Ismaili K; Abramowicz D; Adams B; Godefroid N; Lolin K; Schurmans T; Hall M; Janssen F
Rev Med Brux; 2005; 26(6):505-12. PubMed ID: 16454154
[TBL] [Abstract][Full Text] [Related]
18. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():26-8. PubMed ID: 12091631
[TBL] [Abstract][Full Text] [Related]
19. Maintenance immunosuppression regimens: conversion, minimization, withdrawal, and avoidance.
Yang H
Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S37-51. PubMed ID: 16567240
[TBL] [Abstract][Full Text] [Related]
20. Steroid withdrawal after long-term medication for immunosuppressive therapy in renal transplant patients: adrenal response and clinical implications.
Miozzari M; Ambühl PM
Nephrol Dial Transplant; 2004 Oct; 19(10):2615-21. PubMed ID: 15280521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
